亚太地区非酒精性脂肪性肝病的临床特征与治疗——GO ASIA 研究
GO ASIA 工作组回顾性分析 8 个国家 9 个中心 1008 例经活检证实的非酒精性脂肪性肝病(NAFLD)患者,构建并验证了亚太 NASH 风险评分与亚太 NAFLD 进展性纤维化风险评分,发现结构化生活方式项目、维生素 E 和吡格列酮的使用率有限。
要点
- NASH 独立预测因素包括 BMI≥30 kg/m2、糖尿病、血脂异常、ALT≥88 U/L 和 AST≥38 U/L。
- 进展性纤维化独立预测因素包括年龄≥55 岁、糖尿病和血小板计数<150×10^9/L。
- 仅 1.7% 患者被转介至结构化生活方式项目,4.2% 使用维生素 E,2.4% 使用吡格列酮。
核心结论
- 基于本研究所识别的因素,可怀疑或排除更严重的肝脏疾病。
- 尽管该队列为经活检证实的 NAFLD 患者且多数为 NASH,结构化生活方式项目、维生素 E 和吡格列酮的使用仍然有限。
研究设计与样本
- 回顾性研究,纳入 GO ASIA 工作组中心经活检证实的 NAFLD 患者共 1008 例,来自 8 个国家的 9 个中心。
- 在训练队列中通过二元 logistic 回归分析确定与 NASH 和进展性纤维化相关的独立因素,并据此开发相应风险评分,在验证队列中进行验证。
主要发现
- NASH 占 62.9%,进展性纤维化占 17.2%。
- NASH 的独立预测因素为 BMI≥30 kg/m2、糖尿病、血脂异常、ALT≥88 U/L 和 AST≥38 U/L,构成亚太 NASH 风险评分;高评分的 NASH 阳性预测值为 80%-83%。
- 进展性纤维化的独立预测因素为年龄≥55 岁、糖尿病和血小板计数<150×10^9/L,构成亚太 NAFLD 进展性纤维化风险评分;低评分的进展性纤维化阴性预测值为 95%-96%。
- 仅 1.7% 患者被转介至结构化生活方式项目,4.2% 使用维生素 E,2.4% 使用吡格列酮。
关键数值与推荐
- 亚太 NASH 风险评分高评分的 NASH 阳性预测值为 80%-83%。
- 亚太 NAFLD 进展性纤维化风险评分低评分的进展性纤维化阴性预测值为 95%-96%。
临床怎么用
- 作者认为,基于本研究所识别的因素,可怀疑或排除更严重的肝脏疾病。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Gut and Obesity Asia (GO ASIA) workgroup was formed to study the relationships between obesity and gastrointestinal diseases in the Asia Pacific region. AIM: To study factors associated with nonalcoholic steatohepatitis (NASH) and advanced fibrosis, and medical treatment of biopsy-proven nonalcoholic fatty liver disease (NAFLD) patients. METHODS: Retrospective study of biopsy-proven NAFLD patients from centres in the GO ASIA Workgroup. Independent factors associated with NASH and with advanced fibrosis on binary logistic regression analyses in a training cohort were used for the development of their corresponding risk score, which were validated in a validation cohort. RESULTS: We included 1008 patients from nine centres across eight countries (NASH 62.9%, advanced fibrosis 17.2%). Independent predictors of NASH were body mass index ≥30 kg/m2 , diabetes mellitus, dyslipidaemia, alanine aminotransferase ≥88 U/L and aspartate aminotransferase ≥38 U/L, constituting the Asia Pacific NASH risk score. A high score has a positive predictive value of 80%-83% for NASH. Independent predictors of advanced fibrosis were age ≥55 years, diabetes mellitus and platelet count <150 × 109 /L, constituting the Asia-Pacific NAFLD advanced fibrosis risk score. A low score has a negative predictive value of 95%-96% for advanced fibrosis. Only 1.7% of patients were referred for structured lifestyle program, 4.2% were on vitamin E, and 2.4% were on pioglitazone. CONCLUSIONS: More severe liver disease can be suspected or ruled out based on factors identified in this study. Utilisation of structured lifestyle program, vitamin E and pioglitazone was limited despite this being a cohort of biopsy-proven NAFLD patients with majority of patients having NASH.
引用
- Chan WK, Treeprasertsuk S, Imajo K, et al. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. Aliment Pharmacol Ther. 2018. PMID: 29333610. doi:10.1111/apt.14506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。